U.S. Markets open in 4 hrs 28 mins
  • S&P Futures

    4,393.25
    +13.50 (+0.31%)
     
  • Dow Futures

    34,849.00
    +128.00 (+0.37%)
     
  • Nasdaq Futures

    14,981.25
    +28.50 (+0.19%)
     
  • Russell 2000 Futures

    2,223.90
    +13.00 (+0.59%)
     
  • Crude Oil

    71.59
    +0.33 (+0.46%)
     
  • Gold

    1,813.90
    -8.30 (-0.46%)
     
  • Silver

    25.43
    -0.15 (-0.57%)
     
  • EUR/USD

    1.1886
    +0.0010 (+0.0832%)
     
  • 10-Yr Bond

    1.1740
    0.0000 (0.00%)
     
  • Vix

    18.86
    +0.62 (+3.40%)
     
  • GBP/USD

    1.3913
    +0.0030 (+0.2129%)
     
  • USD/JPY

    109.1460
    -0.1630 (-0.1491%)
     
  • BTC-USD

    38,551.23
    -974.51 (-2.47%)
     
  • CMC Crypto 200

    935.81
    -25.09 (-2.61%)
     
  • FTSE 100

    7,102.10
    +20.38 (+0.29%)
     
  • Nikkei 225

    27,641.83
    -139.19 (-0.50%)
     

Kurin, Inc. Announces Results on Kurin® Efficacy From Oishei Children’s Hospital With Zero Blood Culture Contaminations

·2 min read

SAN DIEGO, July 21, 2021--(BUSINESS WIRE)--Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture collection device with flash technology in a pediatric population. The study was conducted over two periods and in combination, Kurin was used on 1,175 cultures without a single contamination.

"Congratulations to the authors from Oishei Children’s for publishing these important results and for providing this incredible level of care," said Bob Rogers, Inventor and CEO of Kurin. "It is also of note that this is the first study that used our PIV products, which allow nurses the flexibility to draw a culture off a freshly placed IV, which is particularly important in this patient population."

Kurin is the first device to allow for the passive sidelining of the initial flow of blood, providing clinicians a seamless path to compliance. Outcomes are driven by compliance and compliance is a function of how simple technology is integrated into practice, which can be particularly challenging in the busy Emergency Department and on these young patients. Kurin was also designed to use a remarkably low volume of blood, a significant improvement over other options, sidelining just 0.15 ml to achieve these clinical results, another critical requirement for pediatric patients.

"Early on, clinicians at Oishei Children’s gave us feedback on how to modify our product for their patient population, resulting in a small version of our PIV, and using a minimal amount of blood," said Mr. Rogers. "Working with customers to optimize patient health is a meaningful part of why we are here. Our goal is to significantly improve patient outcomes while saving hospitals significant dollars and, given the special place kids have in all of our hearts, it is particularly heartwarming to see the impact that was made here."

About Kurin®, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005097/en/

Contacts

Matt Heindel
Kurin, Inc.
858-752-9514
mattheindel@kurin.com